Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial Article

ESI Most Cited Paper International Collaboration

cited authors

  • Catenacci, Daniel V. T.; Tebbutt, Niall C.; Davidenko, Irina; Murad, Andre M.; Al-Batran, Salah-Eddin; Ilson, David H.; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A.; Udrea, Anghel A.; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang, Rui; Ang, Agnes; Zhang, Yilong; Hoang, Tien; Sidhu, Roger; Cunningham, David

authors

Publication Date

  • November 1, 2017

webpage

published in

category

start page

  • 1467

end page

  • 1482

volume

  • 18

issue

  • 11